miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14

Yiyi Li1,2, Cem Kuscu1, Anna Banach1, Qian Zhang1, Ashleigh Pulkoski-Gross1, Deborah Kim1, Jingxuan Liu3, Eric Roth1, Ellen Li4, Kenneth R. Shroyer5, Paula I. Denoya5, Xiaoxia Zhu2, Longhua Chen2, and Jian Cao1

Abstract

Upregulation of matrix metalloproteinase MMP-14 (MT1-MMP) is associated with poor prognosis in cancer patients, but it is unclear how MMP-14 becomes elevated in tumors. Here, we show that miR-181a-5p is downregulated in aggressive human breast and colon cancers where its levels correlate inversely with MMP-14 expression. In clinical specimens, enhanced expression of MMP-14 was observed in cancer cells located at the invasive front of tumors where miR-181a-5p was downregulated relative to adjacent normal cells. Bioinformatics analyses defined a potential miR-181a-5p response element within the 3'-untranslated region of MMP-14 that was validated in reporter gene experiments. Ectopic miR-181a-5p reduced MMP-14 expression, whereas miR-181a-5p attenuation elevated MMP-14 expression. In support of a critical relationship between these two genes, miR-181a-5p-mediated reduction of MMP-14 levels was sufficient to decrease cancer cell migration, invasion, and activation of pro-MMP-2. Furthermore, this reduction in MMP-14 levels was sufficient to reduce in vivo invasion and angiogenesis in chick chorioallantoic membrane assays. Taken together, our results establish the regulation of MMP-14 in cancers by miR-181a-5p through a posttranscriptional mechanism, and they further suggest strategies to elevate miR-181a-5p to prevent cancer metastasis. Cancer Res; 75(13); 1–12. ©2015 AACR.

Introduction

Metastasis, the dissemination of cancer cells from the primary tumor to a distant organ, accounts for 90% of human cancer-related deaths. Pathologically, metastasis is a multistep process consisting of a series of discrete biologic processes. One of the key biologic steps is cancer cell invasion, which is involved in almost every stage of the metastatic cascade from initiation of metastasis to establishment of a secondary tumor.

Matrix metalloproteinases (MMP) are a family of 25 highly homologous Zn2+-dependent endopeptidases (1). The primary functions of MMPs are traditionally considered to be the degradation of cell adhesion molecules and removal of extracellular matrix (ECM) to permit cancer cell invasion (1). MMPs have been recently recognized as cell migration enhancers, independent of their proteolytic activity (2). Matrix metalloproteinase-14 (MMP-14) is a membrane inserted MMP that has been found to play critical roles in cancer invasion and metastasis by cleaving ECM and basement membrane proteins, activating pro-MMP-2 and -13, inducing the activation of growth factors, and enhancing cell migration (3, 4). Phenotypically, MMP-14 plays a critical role in converting epithelial cells to migratory mesenchymal-like cells (epithelial-to-mesenchymal transition, EMT; ref. 5), which is considered an important mechanism for the initial step in the metastatic process. However, the regulatory mechanism of MMP-14 expression during cancer progression remains to be characterized.

It has been reported that MMP-14 expression is upregulated by transcription factors such as Sp1 and Egr-1 (6, 7). MMP-14 has also been demonstrated to be transcriptionally regulated by hypoxia-inducible factor-2α (8). Not only can MMP-14 expression be positively regulated by these transcription factors, it can also be negatively regulated by microRNA (miRNA, miR), such as miR-9 and -133a (9, 10). miRNAs or miR are small, highly conserved noncoding RNAs that have been reported to participate in the metastatic process by negatively or positively regulating gene expression of metastasis-associated genes through posttranscriptional repression, mRNA degradation, or promoter activation (11). Although miRNAs can positively affect gene expression by binding to the promoter region of a regulated gene, the majority of miRNAs are reported to negatively regulate target gene expression by repressing translation or inducing sequence-specific degradation of target miRNAs.
through interaction with the 3’-untranslated regions (3’-UTR) of target miRNAs (12).

miRNAs are transcribed as approximately 70 nucleotide precursors and subsequently processed by the RNAse-III type enzyme Dicer to give a approximately 22 nucleotide mature product (13). More than 1,500 miRNA genes have been identified in the human genome that collectively control an estimated 30% of all human genes (13). Each miRNA appears to regulate the expression of tens to hundreds of genes to efficiently coordinate multiple cellular pathways. Interestingly, many miRNAs exist as a multi-member family, indicating their functional redundancy.

miR-181a-5p belongs to the miR-181s family, which includes four highly conserved mature miRNAs: miR-181a, b, c, and d. They are derived independently from six precursors located on three different chromosomes. This new class of genes has recently been shown to play a central role in malignant transformation (14, 15). In contrast, miR-181s are downregulated in many tumors and thus appear to function as tumor suppressor genes (16-18).

In this study, we identified miR-181a-5p as a negative regulator of MMP-14 by directly targeting the 3’-UTR of MMP-14 mRNA, resulting in decreased cell migration, invasion, and angiogenesis. Our data highlight a functional role of miR-181a-5p in cancer dissemination and uncover a potential prognostic biomarker and molecular target for the prevention of cancer metastasis.

Materials and Methods

Cell culture and transfection

All cell lines were purchased from the ATCC and were maintained in DMEM medium containing 10% FBS under a 5% CO2 atmosphere. Human breast cancer stem-like SK-3rd cells were maintained as previously described (19). Transfection of plasmid DNA to recipient cells was achieved using polyethylenimine (Polysciences) and the transfected cells were incubated for 48 hours at 37°C followed by biochemical and biologic assays unless otherwise stated.

Immunohistochemistry

Formalin-fixed, paraffin-embedded (FFPE) tissue sections (5 μm) from Stony Brook University Research Histology Core Lab approved by the Institutional Review Board of Stony Brook University (Stony Brook, NY) were examined by a modified IHC method (20). Antigen retrieval was achieved by boiling tissue sections for 30 minutes in 0.01 mol/L sodium citrate, pH 4. Sections were blocked for 1 hour in 1% BSA at room temperature and incubated in rabbit anti-MMP-14 antibodies at 4°C overnight. After washing, sections were incubated with horseradish peroxidase (HRP)–conjugated anti-rabbit IgG, and then by Bio-tin-XX-Tyramide amplification (Invitrogen), and streptavidin–HRP. Stained sections were visualized using 3,3’-diaminobenzidone tetrahydrochloride (DAB) and counterstained with hematoxylin. IHC staining without primary antibody was used as a negative control.

Dot-based cell migration assay

Transfected cells were mixed with an equal volume of neutralized matrigel (3 mg/mL) on ice. The cell–matrigel mixture (1 μL of 1 × 10^7 cell/mL) was then dotted onto a 96-well plate.

After solidification of cell–matrigel hemispheres, the cell–matrigel hemispheres were covered with 100 μL of complete media and incubated for 8 hours, followed by staining with nuclear dye Hoechst and counting of the migrated cells using Nikon NIS-Elements imaging software.

Results

MMP-14 is upregulated in various human cancers

Upregulated MMP-14 expression in cancer cells has been shown to promote tumor growth and metastasis (4). Although MMP-14 has been reported to be upregulated in various human cancers (21), there is no systematic analysis of MMP-14 expression in different cancers from different organs. By mining DNA microarray databases at Oncomine (Cancer Profiling Database), expression of MMP-14 in human cancer specimens was assessed. When assigning a P < 0.01 limit, a myriad of cancers displayed upregulation of MMP-14 as compared with respective normal nonmalignant control tissues (Fig. 1A; refs. 22-31).

To validate the data mining results, human breast cancer specimens were examined for the expression of MMP-14 by examining mRNA and protein levels. A laser capture microdissection (LCM) technique was used to harvest breast carcinoma cells and tumor-adjacent normal epithelial cells as we previously used (32) followed by real-time RT-PCR for the mRNA of MMP-14. Our data show that MMP-14 is selectively expressed in human breast ductal carcinoma in situ (DCIS) and in invasive ductal carcinoma, but not in normal epithelial cells. Expression of MMP-14 in invasive ductal carcinoma is elevated as compared with DCIS, although there is no statistical significance among them (Fig. 1B). To confirm this observation, IHC was performed in the corresponding human breast cancer specimens using an anti–MMP-14 antibody. In agreement with the real-time RT-PCR data, MMP-14 protein was detected only in human breast cancer cells but not in adjacent normal epithelial cells (Fig. 1C).

To further confirm our data mining results showing that the upregulation of MMP-14 is a general phenomenon in cancer, human colon cancer specimens were examined by IHC using the anti–MMP-14 antibody. We observed that MMP-14 is minimally expressed in normal colonic mucosal cells, but increased intensity of staining is found in cancer cells at the invasive front (Fig. 1D and E). Thus, our study indicates that MMP-14 is upregulated in human cancers and the expression level of MMP-14 is correlated with the invasive status of human cancer.
Computational prediction of miR-181s as potential regulators of MMP-14

MMP-14 is upregulated in human cancers; however, the regulatory mechanism of MMP-14 remains to be fully characterized. When MMP-14-GFP chimeric cDNA (MMP-14-GFP) containing the 3′-UTR of MMP-14 (MMP-14-GFP/3′-UTR) was transfected into minimally invasive human breast cancer MCF-7 and highly invasive MDA-MB-231 cells, we noticed that the expression of MMP-14-GFP in MCF-7 cells is relatively weak as compared with that in MDA-MB-231 cells (Fig. 2A, top). This difference, however, was not seen in these cells when transfected with the MMP-14-GFP chimera that does not contain the 3′-UTR (Fig. 2A, bottom). This observation is reproduced in prostate cancer cell lines of LNCaP (minimally invasive) and DU145 and PC3 (highly invasive; Fig. 2B), suggesting that the 3′-UTR of MMP-14 mRNA may contain a regulatory sequence(s) that is responsible for differential expression of MMP-14 in cancer lines.

It is known that the 3′-UTR often contains miRNA response elements (MRE), which are sequences to which miRNAs bind. To identify putative MREs within the 3′-UTR of MMP-14 mRNA, we used TargetScan to search for potential MREs within the 3′-UTR. This analysis revealed multiple MREs that potentially interact with miR-22, -24, -26, -133, -150, and -181s. To increase the probability of postulated MREs within the 3′-UTR, another miRNA prediction algorithm, miRanda, was used. By analyzing predicted MREs from both TargetScan and miRanda, only miR-133 and -181s were found to overlap between the two computational analyses. The MRE of miR-181 within the 3′-UTR between 291 nt and 297 nt received the highest prediction score for binding to miR-181s (Fig. 2C), and hence miR-181s were further characterized.

Interference of ectopically expressed MMP-14 by miR-181a-5p

Because miR-181 isoforms contain identical seed sequence to the MMP-14 3′-UTR (Fig. 2C), miR-181a-2 along with the 140-bp flanking regions at both sides of miR-181a-2 was amplified from the chromosomal DNA and the resultant
DNA was cloned into an MDH1-PGK-GFP2.0 retroviral vector that contains a GFP reporter (Addgene). On the basis of recent miRNA nomenclature guidelines (http://www.mirbase.org), we designated the mature sequence of hsa-miR-181a-2 in the vector as miR-181a-5p/GFP. Using a similar strategy, miR-128 that was not predicted to bind the MMP-14 3′-UTR was also cloned in MDH1-PGK-GFP2.0 retroviral vector as a control (miR-128/GFP). Ectopic expression of miR-181a-5p was examined by transient transfection of the cDNAs encoding miR-181a-5p/GFP as well as control vectors into COS-1 cells, which do not express detectable endogenous MMP-14 (33). Mature miR-181a-5p and -128 were detected in the transfected COS-1 cells by a real-time RT-PCR approach with 5- and 7-fold increases of miR-181a-5p and -128, respectively, as compared with vector control (Fig. 3A), indicating that mature miR-181a-5p and -128 are efficiently produced in the transfected cells.

We then examined whether miR-181a-5p can affect ectopically expressed MMP-14 in COS-1 cells by cotransfecting MPP-14/3′-UTR with miR-control, miR-181a-5p/GFP, and miR-128/GFP, respectively. To increase the expression efficiency for both miRNA and MMP-14/3′-UTR, COS-1 cells were first made to stably express each miRNA and was followed by transient transfection of MMP-14/3′-UTR cDNA and vector control. Ectopic expression of miR-181a-5p, but not miR-control and miR-128, led to reduced MMP-14 mRNA and protein levels (Fig. 3B and C), suggesting that MMP-14 mRNA is downregulated by miR-181a-5p.

To further determine whether the loss of MMP-14 expression in both mRNA and protein levels by miR-181a-5p is due to the existence of the MMP-14 3′-UTR, we used a previously generated plasmid DNA encoding only the open reading frame of MMP-14, and therefore lacks the 3′-UTR of MMP-14 (34). Western blotting revealed that there was no distinct difference in ectopic MMP-14 expression between the cells that overexpressed either miR-181a-5p or miR-control (Fig. 3D), confirming the existence of a miR-181 response element within the 3′UTR.

To further validate the role of miR-181a-5p in regulation of MMP-14 expression, we generated U6 promoter-driven sponge to downregulate miR-181a-5p (Fig. 3E). When the sponges were stably introduced into MCF-7 cells that express a high level of endogenous miR-181a-5p, we found that the sponges efficiently...
reduced the miR-181a-5p level in the cells as compared with the control (Fig. 3F).

To determine whether reduced endogenous miR-181a-5p by the sponges leads to enhanced MMP-14 expression, endogenous and ectopically expressed MMP-14 were examined. It has been reported that hypoxia induces MMP-14 expression (8). When MCF-7 cells stably expressing the sponges were cultured under hypoxic conditions (1% O2) for 48 hours, endogenous MMP-14 increased in cells expressing miR-181a-5p sponges as compared with control sponges (Fig. 3G). To further validate the role of the miR-181a-5p in regulating MMP-14 expression, the effect of miR-181a-5p on ectopic MMP-14 was examined. MCF-7 cells stably expressing the sponges were transfected with MMP-14-GFP/3′-UTR and subsequently analyzed for the MMP-14-GFP mRNA and protein expressions. Ectopic expression of miR-181a-5p sponge, but not the miR-control sponge, led to upregulated MMP-14 in both mRNA and protein levels (Fig. 3H and I), further suggesting that MMP-14 is negatively regulated by miR-181a-5p.

Direct interaction of miR-181a-5p in the MMP-14 3′-UTR

To determine whether miR-181a-5p targets the MMP-14 3′-UTR directly, we used a luciferase reporter gene fused to a sequence of the 3′-UTR of MMP-14 that contains the predicted miR-181a-5p response element (Luc/3′-UTR). As a control, the predicted miR-181a-5p response element (7 nt) was converted to the complementary sequence to eliminate potential miR-181a-5p binding by using a site-direct mutagenesis approach (Luc/3′-UTRmut; ref. 2). Expression of miR-181a-5p significantly
reduced luciferase activity of Luc/3′-UTR, whereas it had no effect on cells expressing miR-control or Luc/3′-UTRmu (Fig. 4A). When Luc/3′-UTR reporter gene was transfected into MCF-7 cells stably expressing miR-181a-5p sponges, the luciferase activity significantly increased as compared with miR-control sponge infected cells, whereas luciferase activity from Luc/3′-UTRmu was not affected by miR-181a-5p sponge (Fig. 4B). Hence, the observed downregulation of MMP-14 by miR-181a-5p depends directly on a single cognate recognition site in the 3′UTR of MMP-14 mRNA.

Using an imaging-based assay, we observed that fluorescence intensity in COS-1 cells coexpressing MMP-14-GFP/3′-UTR with miR-control sponge significantly decreased as compared with control (Fig. 4C and D). Conversely, fluorescence intensity of MMP-14-GFP/3′-UTR in MCF-7 cells stably expressing the miR-181a-5p sponge significantly increased as compared with the control sponge (Fig. 4E).

Effect of functional MMP-14 by miR-181a-5p

We previously reported that functional MMP-14 enhances proteolytic activity and cell migratory ability (3). MMP-2, a secretory MMP that promotes cancer invasion and metastasis, has been used as an indicator for functional MMP-14 (35). We then examined whether reduced MMP-14 expression by miR-181a-5p results in decreased MMP-2 activation and cell migration. Coexpression of MMP-14/3′-UTR with miR-181a-5p/GFP in COS-1 cells resulted in reduced proMMP-2 activation as demonstrated by decreased intermediate (intMMP-2) and fully activated (actMMP-2) MMP-2, along with increased latent...
MMP-2 (proMMP-2) as compared with cells expressing miR-control and miR-128 (Fig. 5A). This decrease correlates with reduced MMP-14 expression (Fig. 3C). Because TIMP-2 is a natural inhibitor of MMP-14 (4), we examined whether the decreased activity of MMP-14 by miR-181a-5p is due to upregulated TIMP-2. Our Western blotting data rules out that possibility because miR-181a-5p does not enhance TIMP-2 expression in MDA-MB-231 cells (Fig. 5B).

Consistent with MMP-2 activation, ectopic expression of miR-181a-5p/GFP along with MMP-14/3' UTR in COS-1 cells led to a decrease in cell migration (Figs. 5C and D). Importantly, miR-128 was unable to inhibit migration in the COS-1 cells expressing MMP-14/3' UTR (Fig. 5C and D), suggesting that miR-181a-5p is a key factor in control of MMP-14 expression, whose down-regulation results in decreased proteolytic potential and cell migratory ability.

Inverse correlation of miR-181a-5p and MMP-14 in human cancer cell lines and human cancer specimens

It has been reported that upregulated MMP-14 is often observed in invasive human cancers and correlates with aggressiveness of human cancer cell lines (21, 36, 37). To investigate the correlation between the endogenous miR-181a-5p level and MMP-14 expression in human cancer cell lines, we surveyed human cancer cell lines using real-time RT-PCR and Western blotting. As expected, MMP-14 expresses at a relatively high level in aggressive cancer cell lines, including HT1080, MDA-MB-231, and breast cancer stem SK-3rd cells (Fig. 6A and B). Interestingly, miR-181a-5p expression is significantly lower in these cells as compared with less aggressive cancer cell lines, such as MCF-7 and SK-BR3 lines (Fig. 6C). To determine clinical significance, we examined the correlation between miR-181a-5p and MMP-14 in human cancer specimens. Because MMP-14 is minimally expressed in normal primary colonic mucosal cells, but an increased intensity of staining is found in cancer cells located at the invasive front (Fig. 1E), we harvested tumor cells at the invasive front of human colon cancer specimens as well as tumor-adjacent normal epithelial cells using a macrodissection technique followed by real-time RT-PCR for miR-181a-5p. Consistent with the observation in cell lines (Fig. 6C), miR-181a-5p is downregulated in invasive tumor cells as compared with tumor-adjacent normal epithelial cells (Fig. 6D). These data suggest that expression of MMP-14 in human invasive cancer is affected by miR-181a-5p levels. To further delineate the causal relationship between miR-181a-5p and MMP-14 expression in cancer progression, we used MDA-MB-231 cells because this cell line is highly invasive and expresses a high level of endogenous MMP-14 (Fig. 6G and H). Specific downregulation of MMP-14 expression has been shown to significantly inhibit cancer cell migration and

Figure 5.
Effect on functional MMP-14 by miR-181a-5p. A, the conditioned medium from COS-1 cells transfected with a combination of DNAs as indicated was examined by gelatin zymography. B, conditioned medium and cell lysates were harvested from COS-1 cells transfected with vector control or TIMP-2 cDNA and MDA-MB-231 cells stably expressing miR-control or miR-181a-5p and followed by Western blotting using an anti-TIMP-2 antibody (top). The membrane was stripped and then probed with an anti-tubulin antibody as a loading control (bottom). C and D, COS-1 cells cotransfected with cDNAs as indicated were examined by a dot-based cell migration assay. Migrated cells within the migration zone were microscopically counted using the Nikon NIS Elements software (C). Representative images are shown (D).
invasion, even though other MMPs continued to be expressed (38). Therefore, we asked whether miR-181a-5p can affect cancer cell migration. Expression of miR-181a-5p in MDA-MB-231 cells resulted in a significant decrease in cell migration as examined by a Transwell chamber migration assay (Fig. 7A). The ability of miR-181a-5p to reduce cell migration was further confirmed in HT1080 cells ectopically expressing miR-181a-5p (Fig. 7B).

Because cell migration is a critical determinant of cancer invasion, a three-dimensional (3D) invasion assay (39) was used to determine whether overexpression of miR-181a-5p in MDA-MB-231 cells and HT1080 cells could inhibit cell invasion. As expected, when overexpressing miR-181a-5p, cell invasive ability was dramatically decreased in both cell lines (Fig. 7C and D).

Because MMP-14 is a transmembrane protease, we next asked whether reduced cancer cell migration and invasion by miR-181a-5p were due to the loss of cell surface MMP-14. By cell surface biotinylation assay, we found that cell surface MMP-14 was markedly reduced in HT1080 cells ectopically expressing high levels of miR-181a-5p (Fig. 7E).

Overexpression of miR-181a-5p attenuates in vivo invasion and angiogenesis

MMP-14 is linked to enhanced cancer invasion (40). To directly examine whether miR-181a-5p is capable of inhibition of MMP-14–mediated cancer cell invasion through basement membrane in vivo, the chick chorioallantoic membrane (CAM) invasion assay was used (40). The CAM consists of the chorionic epithelium and underlying allantoic membrane that is primarily made of type IV collagen (41), which simulates the basement membrane of human epithelium (42). Invasion of cancer cells through the epithelium and basement membrane of the upper CAM into connective tissue was examined by hematoxylin and eosin staining. miR-control MDA-MB-231 cells that were loaded onto the CAM invaded into the connective tissues through the breached basement membrane (Fig. 7F). In contrast, MDA-MB-231 cells stably expressing MMP-14 expressed high levels of MMP-14 (Fig. 6).

The effect of miR-181a-5p on MMP-14 expression was examined (Fig. 7G and H). The effect on MMP-14 expression in MDA-MB-231 cells expressing miR-181a-5p was examined by real-time RT-PCR (F, left) or Western blotting (F, right). G and H, expression of miR-181a-5p in HT1080 cells was examined by real-time RT-PCR (G) and MMP-14 expression in the HT1080 cells was examined by real time RT-PCR and Western blotting (H).
miR-181a-5p failed to cross through the basement membrane. In addition, more new blood vessels underneath the CAM can be found in miR-control cells as compared with miR-181a-5p cells. This reduction in invasion, along with the decrease in angiogenesis, suggests that miR-181a-5p is effective at interfering with the in vivo invasive ability of MDA-MB-231 cells, which normally express high levels of MMP-14.

To further characterize the antiangiogenic activity of miR-181a-5p through downregulation of MMP-14 expression, HT1080 cells were used. Because minimal miR-181a-5p is present in HT1080 cells, we stably expressed miR-181a-5p in HT1080 cells and applied the cells over chorioallantoic membranes via sponges as previously described (19, 38). miR-181a-5p, but not miR-control, statistically impaired new blood vessel formation induced by HT1080 cells (Fig. 7G).

Taken together, we, for the first time, demonstrate that miR-181a-5p is a critical regulator for MMP-14 expression and can affect MMP-14-mediated cancer cell migration, invasion, and angiogenesis.

**Discussion**

In this study, we first validated that MMP-14 is highly upregulated in human breast and colon cancers. We then demonstrated that miR-181a-5p is inversely correlated with MMP-14 expression and the invasive capacity of cancer cell lines. We also identified the miR-181a-5p target sequence within the MMP-14 3\’-UTR that is responsible for the stability of MMP-14 mRNA. Ectopic expression of miR-181a-5p resulted in downregulation of both endogenous and exogenous MMP-14 expression,
leading to decreased cell migration, invasion, and angiogenesis. Although MMP-14 is transcriptionally regulated by activating the gene’s promoter (7), the effect of the stability of MMP-14 mRNA is another key regulatory mechanism in controlling MMP-14 expression. Hence, our observations unravel the posttranscriptional regulatory mechanism for MMP-14 expression.

miRNAs can induce gene expression by binding to the 5’-UTR of the promoter region of targeted genes or reduce gene expression by binding to the 3’-UTR of the target gene and allowing for mRNA degradation or preventing mRNA from being translated. Our data indicate that miR-181a-5p negatively affects MMP-14 expression through binding to the 3’-UTR of MMP-14. Because MMP-14 mRNA is reduced by miR-181a-5p, it is assumed that miR-181a-5p induces MMP-14 mRNA degradation, rather than blocking MMP-14 protein translation. Because upregulation of MMP-14 directly associates with cancer aggressiveness, induction of endogenous miR-181a-5p provides a potential approach to prevent cancer invasion and metastasis. However, it should be pointed out that the role of miR-181a in cancer is still controversial depending on the tumor type.

Several studies have indicated that miR-181s serve as tumor-promoting genes, but the function of miR-181a-5p is tumor-type specific. miR-181a-5p was found to be upregulated in gastric and liver cancers (43, 44) and in two separate studies, miR-181a-5p overexpression was reported to enhance ovarian, liver, and breast cancer progression through different mechanisms (14, 15, 45). However, miR-181s have also been suggested as tumor suppressors in several types of human cancers including leukemia, glioma, and oral squamous cell carcinoma (16–18). These controversial observations suggest the complexity of miRNAs and the function of specific miRNAs can differ markedly depending on tumor types. It is worth noting that most of these studies use the bulk of human tumor tissues that contain not only tumor cells, but also several stromal cell types and adjacent normal epithelial cells. This may not faithfully represent the expression level of specific miRNAs in cancer. Indeed, our data support this notion by showing that miR-181a-5p and MMP-14 are differentially expressed in invasive tumor cells and tumor-adjacent normal epithelial cells.

Although this study focuses on miR-181a-5p because it received the highest probability score by computational analysis, other miRNAs may also affect MMP-14 expression. Akano et al. (40) reported that miR-133 reduces MMP-14 expression, leading to decreased cancer cell migration and invasion. Because we also identified a miR-133 response element within the 3’-UTR of MMP-14 mRNA by miRNA prediction algorithms, Akano’s report supports our bioinformatics analysis. Another miRNA, miR-9, was recently reported to downregulate MMP-14 expression by targeting the 3’-UTR, resulting in decreased cellular invasion and metastasis in neuroblastoma cells (9). Although two separate miRNA prediction algorithms were used to identify MREs within the MMP-14 3’-UTR in our study, we did not observe the miR-9 response element within the MMP-14 3’-UTR. Interestingly, miR-9 was also reported to directly target CDH1, the E-cadherin—encoding mRNA, leading to increased cell motility and invasiveness, which ultimately contributes to metastasis (46). Because mounting evidence indicates that MMP-14 cleaves E-cadherin at the cell surface, leading to enhanced cancer aggressiveness (5), both reports seem contradictory under pathologic conditions. Questions remain as to whether these miRNAs synergistically or individually affect MMP-14 gene expression leading to reduced cell invasion.

Upregulation of MMP-14 in cancer has been recognized as one of the critical mechanisms of cancer dissemination. The expression of MMP-14 has been detected in tumor cells and adjacent stromal cells in a variety of human tumors (21). Using in situ hybridization techniques, several reports have demonstrated that MMP-14 is mostly expressed in stromal cells within tumors or expressed in both cancer cells and surrounding fibroblasts and macrophages (47, 48). In our IHC, we found MMP-14 exclusively expressed in cancer cells. Our real-time RT-PCR data examining laser microdissected cancer cells support our IHC data. Interestingly, we found that MMP-14 expresses at a low level in primary colon cancer cells, whereas expression of MMP-14 dramatically increases in colon cancer cells located at the invasive front or those that have already invaded into the submucosa. Because MMP-14 plays a critical role in cancer cell EMT (5), our data support the notion that tumor cells at the invasive front gradually change their phenotype to facilitate invasion into surrounding tissues.

In light of the pivotal role of MMP-14 in cancer progression, the current report provides scientific evidence for inducing endogenous miR-181a-5p expression to suppress MMP-14-mediated cancer cell migration, invasion, and angiogenesis. However, because miR-181a-5p can potentially target over 500 different mRNAs (as analyzed by PicTar prediction algorithm) and miR-181a-5p–targeted genes may exert differential or even opposing effects in different cellular contexts, the challenge ahead is to resolve inconsistent observations that exist and unify the current data into a coherent mechanism for miR-181a-5p function within particular tumor types. Interestingly, recent studies using a DNA microarray or quantitative mass spectrometry approach indicate that the repression of mRNAs and proteins by a miRNA is often relatively small (less than 2-fold and rarely exceeds 4-fold; refs. 49, 50). Given the technical limitation, the only way to validate the effects of reduced gene expression by a miRNA on cellular phenotypic changes is to characterize the miRNA-targeted gene individually. Nevertheless, our findings identify an additional posttranscriptional mechanism for regulating MMP-14 expression and indicate that downregulated expression of miR-181a-5p may contribute to cancer invasion and angiogenesis in certain tumors.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: C. Kuscu, E. Roth, L. Chen, J. Cao Development of methodology: Y. Li, C. Kuscu, D. Kim, E. Roth, J. Cao Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Li, A. Banach, Q. Zhang, D. Kim, J. Liu, E. Li, P. I. Denoya Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Li, C. Kuscu, A. Banach, Q. Zhang, E. Li, K.R. Shroyer, J. Cao Writing, review, and/or revision of the manuscript: Y. Li, A. Pulkoski-Gross, E. Li, K.R. Shroyer, J. Cao Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): X. Zhu Study supervision: X. Zhu, L. Chen, J. Cao
Grant Support

This work is supported, in part, by the Baldwin Breast Cancer Foundation and the National Cancer Institute (1R01CA169366 to J. Cao), The Simons Foundation (E. Li), the National Natural Science Foundation of China (81272507/H1610 to L. Chen), and the Excellent Young Teachers Program of Higher Education of Guangdong Province (Yq2013040 to X. Zhu).

References


miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14

Yiyi Li, Cem Kuscu, Anna Banach, et al.

Cancer Res. Published OnlineFirst May 14, 2015.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-2875

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2015/05/15/0008-5472.CAN-14-2875.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2015/06/16/0008-5472.CAN-14-2875. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.